The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients
(Source: Annals of Hematology)
Source: Annals of Hematology - March 1, 2021 Category: Hematology Source Type: research

Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis
In conclusion, despite the absence of clear evidence, our analysis shows that AP in patients with ITP receiving RTX is frequently adopted, even if in the absence of well-defined criteria. Prophylaxis administration is quite consistent within the same haematological Center; thus, it seems related to clinicians ’ experience. (Source: Annals of Hematology)
Source: Annals of Hematology - February 27, 2021 Category: Hematology Source Type: research

Hematologic changes predict clinical outcome in recovered patients with COVID-19
Abstract2019 coronavirus disease (COVID-19) presents as a newly recognized pneumonia that has brought about a global pandemic and is increasingly considered as a systemic illness. We investigated the clinical and laboratory features of recovered COVID-19 patients without pre-existing hematologic diseases at Wuhan No. 1 Hospital. Fifty-nine male and 68 female Chinese patients were included with the median age at 64 years in the present study. Eosinopenia (37.80%), monocytosis (51.97%), lymphocytopenia (25.20%), and anemia (51.97%) were the most common hematologic findings in our cohort, particularly in severe or critically ...
Source: Annals of Hematology - February 27, 2021 Category: Hematology Source Type: research

Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis
AbstractAllogeneic hematopoietic cell transplant (allo-HCT) is a potentially curative therapeutic strategy that showed encouraging long-term outcomes in hematological diseases. A number of factors can influence post-transplant clinical outcomes. While Epstein-Barr virus (EBV) constitutes a trigger for development of various adverse conditions, no clinical study yet has been powered to assess the effect of EBV serostatus on the clinical outcomes in allo-HCT population. To systematically summarize and analyze the impact of donor and recipient EBV serostatus on transplant outcomes in allo-HCT recipients, meta-analyses were co...
Source: Annals of Hematology - February 27, 2021 Category: Hematology Source Type: research

Acute lymphoblastic leukemia –like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients
This study aimed to characterize MPAL cases with special emphasis on comparing adult and pediatric age groups, exploring treatment regimens, and clinical outcome. Among 2571 acute leukemia patients, 102 MPAL cases fulfilling the 2008/2016 WHO diagnostic criteria of MPAL were recruited in the study. The incidence of MPAL was 4% of acute leukemia patients. Pediatric cases were 54 (53%) while adults were 48/102 (47%). Myeloid/B-lymphoid phenotype was found in 86/102 (84%), with BCR-ABL fusion gene transcript detected in 14/102(13.7%) patients. ALL-like treatment showed better response rates as compared with the myeloid based ...
Source: Annals of Hematology - February 27, 2021 Category: Hematology Source Type: research

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from W ürzburg and Wuhan
(Source: Annals of Hematology)
Source: Annals of Hematology - February 27, 2021 Category: Hematology Source Type: research

A rare cause of respiratory failure in acute myeloid leukaemia patient
(Source: Annals of Hematology)
Source: Annals of Hematology - February 27, 2021 Category: Hematology Source Type: research

Dynamic evaluation of the prognostic value of 18 F-FDG PET/CT in extranodal NK/T-cell lymphoma, nasal type
AbstractExtranodal natural killer/T-cell lymphoma, nasal-type (ENKTL) is a type of rare and distinct entity of non-Hodgkin lymphoma with poor prognosis. It is important to evaluate the early treatment response accurately to decide further treatment strategy.18F-FDG PET/CT plays an important role in response evaluation and prognostic prediction in some kinds of lymphomas. However, data available regarding patients with ENKTL are limited. Thus, in this prospective study, we analyzed the prognostic value of18F-FDG PET/CT in ENKTL. Thirty-four patients with newly diagnosed ENKTL were enrolled in this phase 2 study (NCT02825147...
Source: Annals of Hematology - February 26, 2021 Category: Hematology Source Type: research

Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80 —results from a single-center survey
AbstractThe prognosis of elderly patients diagnosed with diffuse large B cell lymphoma (DLBCL) is considered to be clearly inferior to that of younger patients. Besides tumor biology and comorbidities, treatment selection due to an assumed reduced tolerability may contribute to this difference. With increasingly more patients diagnosed at advanced age, current treatment selections need to be reviewed carefully. Hence, we analyzed the results of patients above the age of 70 in whom a diagnosis of DLBCL was made. Whereas patients up to 80 were frequently selected for and were able to tolerate standard treatment (86% intended...
Source: Annals of Hematology - February 25, 2021 Category: Hematology Source Type: research

Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma
AbstractFrailty and concurrent medical conditions are crucial factors in the management of follicular lymphoma (FL). We evaluated the impact of age and comorbidity on survival, causes of death, histological transformation (HT), and second malignancies (SM) in a large single-center series of grade 1 –3A FL. We studied 414 patients diagnosed in the rituximab era, categorized into three age groups (≤60, 61–70,>70 years) and two comorbidity groups (Charlson Comorbidity Index, CCI, 0 –1 and ≥2). Despite a similar cumulative incidence of relapse, older and comorbid patients had a lower 10-year overall ...
Source: Annals of Hematology - February 25, 2021 Category: Hematology Source Type: research

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
AbstractThe optimal salvage therapy in relapsed/refractory Hodgkin lymphoma (R/R HL) has not been defined so far. The goal of this multicenter retrospective study was to evaluate efficacy and safety of BGD (bendamustine, gemcitabine, dexamethasone) as a second or subsequent line of therapy in classical R/R HL. We have evaluated 92 consecutive R/R HL patients treated with BGD. Median age was 34.5 (19 –82) years. Fifty-eight patients (63%) had received 2 or more lines of chemotherapy, 32 patients (34.8%) radiotherapy, and 21 patients (22.8%) an autologous hematopoietic stem cell transplantation (autoHCT). Forty-four pa...
Source: Annals of Hematology - February 24, 2021 Category: Hematology Source Type: research

Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan
In conclusion, single CBT offers a curative option for AML patients aged ≥60 years with careful patient selection. (Source: Annals of Hematology)
Source: Annals of Hematology - February 23, 2021 Category: Hematology Source Type: research

Re: Hosokawa K et al. Assay sensitivity of flow cytometric PNH analysis
(Source: Annals of Hematology)
Source: Annals of Hematology - February 22, 2021 Category: Hematology Source Type: research

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma
The objective of our study was to retrospectively analyze the safety of 2  cycles of systemic HD-MTX administered as an ambulatory regimen. Between January 2013 and December 2016, 103 patients were carefully selected on 6 criteria, including age  34, performance status 0 or 1, normal renal and hepatic functions, good understanding of practical medical guidance, and no loss of weight. Strict procedures of HD-MTX infusion were observed including alkalinization, urine pH monitoring, and leucovorin rescue. Renal and hepatic functions were mon itored at days 2 and 7. MTX clearance was not monitored. Toxicities and g...
Source: Annals of Hematology - February 19, 2021 Category: Hematology Source Type: research

Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids
(Source: Annals of Hematology)
Source: Annals of Hematology - February 18, 2021 Category: Hematology Source Type: research

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
We present a subgroup analysis of Asian patients from COLUMBA. Eligible patients had ≥ 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or were double refractory. Co-primary endpoints were overall response rate (ORR) and maximum trough concentration (Ctrough). Secondary endpoints included rates of infusion-related reactions, progression-free survival, and patient-reported satisfaction with therapy. Sixty-seven Asian patients (DARA SC,n = 30; DARA IV,n = 37) were randomized, including 42 Japanese patients (DARA SC,n = 18; DARA IV,n&t...
Source: Annals of Hematology - February 18, 2021 Category: Hematology Source Type: research

Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis
AbstractA head-to-head comparison of outcomes of unrelated donor allogeneic peripheral blood stem cell transplantation for AML between reduced intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens using thymoglobulin for GVHD prophylaxis is limited. We evaluated outcomes of 122 AML patients who received either busulfan (Bu)/fludarabine (Flu)/low-dose total body irradiation (TBI) as RIC (n = 64, 52%) or Bu/Flu as MAC (n = 58, 48%), and thymoglobulin 4.5 mg/kg total dose between day − 3 to − 1 for GVHD prophylaxis. Grades III–IV acute GVHD (aGVHD) was lower with Bu/Flu/TBI compared with...
Source: Annals of Hematology - February 16, 2021 Category: Hematology Source Type: research

The rare hemoglobin variant Hb Mizuho: report of a Swiss family and literature review
AbstractHb Mizuho is a very rare unstable hemoglobin; here, we describe the clinical history of three Swiss family members with Hb Mizuho together with a systematic review of the previously six published cases. The clinical history of the adult woman we report here is unique since this is the first Hb Mizuho presenting with Moyamoya complications and the first case reported with long-term erythrocyte exchange. The literature review showed that Hb Mizuho was mainly reported as a de novo mutation, with the exception of children descended from known cases. All published patients with this unstable hemoglobin showed severe hem...
Source: Annals of Hematology - February 15, 2021 Category: Hematology Source Type: research

Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis
AbstractChimeric antigen receptor (CAR) T cell therapy improves the remission rate of refractory/relapsed B-acute lymphoblastic leukemia (R/R B-ALL) patients, but the relapse rate remains high. Recent studies suggest patients who underwent post-chimeric antigen receptor T cell therapy hematopoietic stem cell transplantation (post- HSCT) would achieve durable remission and better survival, but this remains controversial. To this end, we conducted a meta-analysis to assess the role of post-HSCT in R/R B-ALL. The Cochrane Library, Embase, and PubMed were used to identify relevant studies; the latest search update was on July ...
Source: Annals of Hematology - February 15, 2021 Category: Hematology Source Type: research

Alpha thalassemia, but not β S -globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort
AbstractAlpha thalassemia and beta-globin haplotype are considered classical genetic disease modifiers in sickle cell anemia (SCA) causing clinical heterogeneity. Nevertheless, their functional impact on SCA disease emergence and progression remains elusive. To better understand the role of alpha thalassemia and beta-globin haplotype in SCA, we performed a retrospective study evaluating the clinical manifestations of 614 patients. The univariate analysis showed that the presence of alpha-thalassemia −3.7-kb mutation (αα/-α and -α/-α) decreased the risk of stroke development (p = 0.046), ...
Source: Annals of Hematology - February 13, 2021 Category: Hematology Source Type: research

Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide
AbstractCytokine release syndrome (CRS), occurring in more than 70% of HLA-haploidentical hematopoietic stem-cell transplantations with post-transplant cyclophosphamide (PT/CY-haplo), can lead to hemodynamic instability and worsen clinical outcomes. A calcineurin inhibitor is initiated after cyclophosphamide administration in the commonly used PT/CY regimens. Here, we conducted a phase I/II, prospective, single-center trial of PT/CY-haplo to evaluate the safety and efficacy of cyclophosphamide on days 3 and 5 along with cyclosporin and mycophenolate mofetil started from day − 1. Thirty-five adults with hematologic ma...
Source: Annals of Hematology - February 12, 2021 Category: Hematology Source Type: research

Rare presentation of myeloma with diffuse osteosclerotic lesions without features of POEMS
(Source: Annals of Hematology)
Source: Annals of Hematology - February 12, 2021 Category: Hematology Source Type: research

Successful treatment by using a modified SMILE regimen and autologous hematopoietic stem cell transplantation in a pediatric primary EBV-positive nodular NK/T cell lymphoma patient
(Source: Annals of Hematology)
Source: Annals of Hematology - February 12, 2021 Category: Hematology Source Type: research

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
AbstractExtramedullary disease (EMD) represents a high-risk state of multiple myeloma (MM) associated with poor prognosis. While most anti-myeloma therapeutics demonstrate limited efficacy in this setting, some studies exploring the utility of chimeric antigen receptor (CAR)-modified T cells reported promising results. We have recently designed SLAMF7-directed CAR T cells for the treatment of MM. SLAMF7 is a transmembrane receptor expressed on myeloma cells that plays a role in myeloma cell homing to the bone marrow. Currently, the only approved anti-SLAMF7 therapeutic is the monoclonal antibody elotuzumab, but its efficac...
Source: Annals of Hematology - February 11, 2021 Category: Hematology Source Type: research

Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia
(Source: Annals of Hematology)
Source: Annals of Hematology - February 11, 2021 Category: Hematology Source Type: research

Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression for ruling out myelodysplastic syndromes: a prospective validation study
This study aimed to prospectively validate the accuracy for flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in ruling out MDS. We enrolled 62 consecutive patients who were referred for suspected MDS, based on medical history and peripheral blood cytopenia. The accuracy of intra-individual robust coefficient of variation (RCV) for peripheral blood neutrophil myeloperoxidase expression was assessed with a prespecified 30% threshold. Cytomorphological evaluation of bone marrow aspirate performed by experienced hematopathologists confirmed MDS in 23 patients (prevalence, 37%), unconfirmed MDS...
Source: Annals of Hematology - February 10, 2021 Category: Hematology Source Type: research

Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA
AbstractSplenectomy is one of the treatments of immune thrombocytopenia (ITP) with a high response rate. However, it is an irreversible procedure that can be associated with morbidity in this setting. Our aim was to study the trends of splenectomy in adults with ITP, and the factors associated with splenectomy and resource utilization during these hospitalizations. We used the National (Nationwide) Inpatient Sample (NIS) to identify hospitalizations for adult patients with a principal diagnosis of ITP between 2007 and 2017. The primary outcome was the splenectomy trend. Secondary outcomes were (1) incidence of ITP trend, (...
Source: Annals of Hematology - February 9, 2021 Category: Hematology Source Type: research

Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation
AbstractPost-transplantation lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT), occurring in a setting of immune suppression and dysregulation. The disease is in most cases driven by the reactivation of the Epstein-Barr virus (EBV), which induces B cell proliferation through different pathomechanisms. Beyond EBV, many factors, variably dependent on HSCT-related immunosuppression, contribute to the disease development. PTLDs share several features with primary lymphomas, though clinical manifestations may be different, frequently depending on extranodal involveme...
Source: Annals of Hematology - February 6, 2021 Category: Hematology Source Type: research

Chronic active Epstein-Barr virus infection of T cell type presenting with hemophagocytic lymphohistiocytosis in a Caucasian adult
(Source: Annals of Hematology)
Source: Annals of Hematology - February 6, 2021 Category: Hematology Source Type: research

Non-transfusion-dependent thalassemia in Italy: less blues, no role of reds
(Source: Annals of Hematology)
Source: Annals of Hematology - February 4, 2021 Category: Hematology Source Type: research

Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group
In this study, we report the experience of the multiple myeloma GIMEMA Lazio Group in 62 relapsed/refractory MM patients treated with daratumumab as monotherapy who had previously received at least two treatment lines including a PI and an IMiDs or had been double refractory. Patients received DARA 16  mg/kg intravenously weekly for 8 weeks, every 2 weeks for 16 weeks, and every 4 weeks until disease progression or unacceptable toxicity. The overall response rate to daratumumab was 46%. Median progression-free survival (PFS) and overall survival reached 2.7 and 22.4 months, respectively. DA RA...
Source: Annals of Hematology - February 2, 2021 Category: Hematology Source Type: research

Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy
(Source: Annals of Hematology)
Source: Annals of Hematology - February 2, 2021 Category: Hematology Source Type: research

Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma
AbstractImmune checkpoint inhibitors (ICI) have demonstrated high therapeutic efficacy in relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, despite the accumulated data, the question of the ICI therapy duration and efficacy of nivolumab retreatment remains unresolved. In this retrospective study, in a cohort of 23 adult patients with r/r cHL who discontinued nivolumab in complete response (CR), the possibility of durable remission achievement (2-year PFS was 55.1%) was demonstrated. Retreatment with nivolumab has demonstrated efficacy with high overall response rate (ORR) and CR (67% and 33.3% resp...
Source: Annals of Hematology - February 2, 2021 Category: Hematology Source Type: research

COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications
AbstractCOVID-19 pandemic has imposed worldwide challenge and has significantly affected transfusion medicine. Shortage in blood products along with concerns regarding the safety of blood products have emerged. Measures to overcome these challenges have been implemented in order to decrease the demand on blood products and to encourage blood donations while taking full precautions to minimize risk of COVID-19 transmission mainly at blood banks and medical centers. Several countries have been successful in facing these new challenges. In addition, the role of plasma therapy in the treatment of COVID-19 patients, especially ...
Source: Annals of Hematology - February 1, 2021 Category: Hematology Source Type: research

Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
We present the mature and extended results of a retrospective study evaluating the prognostic significance of EoT-PET/CT after adequate response to R-CHOP. Among 231 consecutive PMLBCL patients, 182 underwent EoT-PET/CT and were evaluated according to the Deauville 5-point scale (D5PS) criteria. Freedom from progression (FFP) was measured from the time of PET/CT examination. Among 182 patients, 72 (40%) had D5PS score 1 (D5PSS-1), 33 (18%) had 2, 28 (15%) had 3, 29 (16%) had 4, and 20 (11%) had 5. The 5-year FFP was 97, 94, 92, 82, and 44% for D5PSS-1, D5PSS-2, D5PSS-3, D5PSS-4, and D5PSS-5, respectively. Among 105 patient...
Source: Annals of Hematology - February 1, 2021 Category: Hematology Source Type: research

Correspondence in reference to the previously published Epub manuscript: “Murt Ahmet et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology 2020; 99: 2671-2677”
(Source: Annals of Hematology)
Source: Annals of Hematology - February 1, 2021 Category: Hematology Source Type: research

Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation
In conclusion, preemptive low-dose IL2 and preemptive DLI yield comparable outcomes for patients with LMRD receiving allo-HSCT, in terms of aGVHD, NRM, relapse, OS, and DFS. However, preemptive  low-dose IL2 has a lower incidence of moderate/severe cGVHD and a higher CRFS. Preemptive low-dose IL2 may be an alternative method for patients who develop LMRD after allo-HSCT, particularly for patients who cannot receive preemptive DLI. (Source: Annals of Hematology)
Source: Annals of Hematology - January 20, 2021 Category: Hematology Source Type: research

The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
AbstractDespite the increasing inclusion of novel agents within the multiple myeloma (MM) treatment sequence, their role for posttransplant consolidation therapy remains unclear. We systematically reviewed studies evaluating the efficacy of novel agent consolidation. We identified 11 citations on 12 prospective comparative studies, and 5 citations were single-arm or comparative studies with preliminary results. Nine different regimens were evaluated in 5905 patients. Risk assessment yielded serious risk of bias and heterogeneity across study designs was high. Irrespective of the regimen, deepened responses after consolidat...
Source: Annals of Hematology - January 20, 2021 Category: Hematology Source Type: research

Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
AbstractTo ensure the safety of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT), evidence-based recommendations on infectious complications after HDC/ASCT are given. This guideline not only focuses on patients with haematological malignancies but also addresses the specifics of HDC/ASCT patients with solid tumours or autoimmune disorders. In addition to HBV and HCV, HEV screening is nowadays mandatory prior to ASCT. For patients with HBs antigen and/or anti-HBc antibody positivity, HBV nucleic acid testing is strongly recommended for 6  months after HDC/ASCT or for the duration of a respecti...
Source: Annals of Hematology - January 20, 2021 Category: Hematology Source Type: research

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
(Source: Annals of Hematology)
Source: Annals of Hematology - January 20, 2021 Category: Hematology Source Type: research

Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia
(Source: Annals of Hematology)
Source: Annals of Hematology - January 20, 2021 Category: Hematology Source Type: research

Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia
(Source: Annals of Hematology)
Source: Annals of Hematology - January 19, 2021 Category: Hematology Source Type: research

Germline RUNX1 translocation in familial platelet disorder with propensity to myeloid malignancies
(Source: Annals of Hematology)
Source: Annals of Hematology - January 18, 2021 Category: Hematology Source Type: research

HSV1 viremia with fulminant hepatitis as opportunistic sequela in severe COVID-19
(Source: Annals of Hematology)
Source: Annals of Hematology - January 18, 2021 Category: Hematology Source Type: research

The first case of a collision tumor of gastrointestinal stromal tumor and intravascular large B cell lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - January 18, 2021 Category: Hematology Source Type: research

Correction to: Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis
A Correction to this paper has been published:https://doi.org/10.1007/s00277-021-04427-w (Source: Annals of Hematology)
Source: Annals of Hematology - January 18, 2021 Category: Hematology Source Type: research

Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial
AbstractCarfilzomib, lenalidomide, and dexamethasone (KRd) effectively improve survival in patients with relapsed and refractory multiple myeloma (RRMM). However, the outcome of KRd treatment in Asian patients reflecting a general RRMM population outside of a clinical trial has not been reported. Fifty-five RRMM patients who were treated with carfilzomib in combination with Rd from the time of the first approval of KRd in the Republic of Korea were analyzed. The median age was 61 years. The percentage of patients with an ECOG performance status ≥ 3, creatinine clearance
Source: Annals of Hematology - January 15, 2021 Category: Hematology Source Type: research

Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia
This study aims to explore whether variations in normal haematopoiesis determine prognosis as well as to improve risk-stratified treatment in childhood ALL. A retrospective study of 279 cases of ALL treated with the CCCG-ALL-2015 regimen in the Division of Pediatric Blood Diseases Center, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, from May 2015 to January 2017 was performed to analyse the prognostic impact of blood cell levels on day 19 of induction therapy by Kaplan-Meier method. Patients with childhood ALL with absolute neutrophil count (AN...
Source: Annals of Hematology - January 14, 2021 Category: Hematology Source Type: research

HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient
(Source: Annals of Hematology)
Source: Annals of Hematology - January 14, 2021 Category: Hematology Source Type: research

Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial
AbstractPrognosis in patients with post allogeneic HCT-early relapse of acute myeloid leukemia (
Source: Annals of Hematology - January 13, 2021 Category: Hematology Source Type: research